{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-038441","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.246630+00:00","generated_at":"2026-06-04T08:31:09.248514+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioXcel raises $25M in registered direct offering of shares and warrants","bullets":["Sold 3.05M shares at $2.901/share with accompanying warrants, and 5.57M pre-funded warrants at $2.900/share with accompanying warrants.","Net proceeds of ~$24.9M to fund BXCL501 clinical trials, IGALMI commercialization, and general corporate purposes.","Accompanying warrants have $3.20 exercise price, 5-year term; closing expected March 27, 2024.","Offering conducted under existing Form S-3 shelf registration; Latham & Watkins provided legal opinion."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-038441","json":"https://secwatch.observer/filing/0001104659-24-038441.json","markdown":"https://secwatch.observer/filing/0001104659-24-038441.md","text":"https://secwatch.observer/filing/0001104659-24-038441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924038441/0001104659-24-038441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924038441/tm249625d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:31:09.248514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ed7193442e5fde2253b183eb714226f29f4b53f","claim":"BioXcel Therapeutics, Inc. entered into Securities Purchase Agreement with the purchasers named therein (collectively, the \"Purchasers\") valued at approximately $24.9 million (effective 2024-03-25).","evidence_excerpt":"On March 25, 2024, BioXcel Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (collectively, the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924038441/0001104659-24-038441-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein (collectively, the \"Purchasers\")"},{"label":"Value","value":"approximately $24.9 million"},{"label":"Effective","value":"2024-03-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}